Amneal Pharmaceuticals (AMRX) Financials

$7.18 +0.01 (+0.14%)

As of 04:00 PM Eastern

Annual Income Statements for Amneal Pharmaceuticals

This table shows Amneal Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	0.00	0.00	-21	-362	91	11	-130	-84	-117
Consolidated Net Income / (Loss)	209	169	-201	-604	69	20	-255	-49	-74
Net Income / (Loss) Continuing Operations	209	169	-201	-604	69	20	-255	-49	-74
Total Pre-Tax Income	215	171	-203	-220	-36	31	-248	-40	-55
Total Operating Income	285	245	-20	-249	91	153	-95	204	249
Total Gross Profit	597	526	716	353	628	769	785	821	1,020
Total Revenue	1,018	1,034	1,663	1,626	1,993	2,094	2,212	2,394	2,794
Operating Revenue	1,018	1,034	1,663	1,626	1,993	2,094	2,212	2,394	2,794
Total Cost of Revenue	421	507	947	1,273	1,364	1,325	1,428	1,573	1,774
Operating Cost of Revenue	421	507	947	1,273	1,364	1,325	1,428	1,573	1,774
Total Operating Expenses	313	281	736	602	537	616	880	616	771
Selling, General & Admin Expense	119	109	228	290	327	366	400	430	476
Research & Development Expense	179	171	194	188	180	202	200	168	197
Other Operating Expenses / (Income)	-	21	16	14	11	7.72	-5.87	-1.14	0.00
Impairment Charge	0.00	0.00	39	47	2.68	0.71	13	31	0.00
Restructuring Charge	0.07	9.40	278	51	11	15	2.13	1.75	2.36
Other Special Charges / (Income)	15	-29	-20	12	5.86	25	271	-13	96
Total Other Income / (Expense), net	-70	-74	-183	28	-127	-121	-153	-245	-304
Interest Expense	0.00	2.53	20	-	0.00	0.00	0.29	41	0.00
Interest & Investment Income	-55	-71	-144	-168	-146	-136	-158	-211	-259
Other Income / (Expense), net	-15	-0.19	-20	197	19	15	5.47	6.79	-46
Income Tax Expense	5.40	2.00	-1.42	383	-104	11	6.66	8.45	19
Preferred Stock Dividends Declared	0.00	0.00	1.18	-	0.00	0.00	0.44	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	2.05	1.68	-33	-242	-22	9.55	-125	35	43
Basic Earnings per Share	$0.00	-	($0.16)	($2.74)	$0.62	$0.07	($0.86)	($0.48)	($0.38)
Weighted Average Basic Shares Outstanding	0.00	-	127.25M	132.11M	147.44M	148.92M	150.94M	176.14M	308.98M
Diluted Earnings per Share	$0.00	-	($0.16)	($2.74)	$0.61	$0.07	($0.86)	($0.48)	($0.38)
Weighted Average Diluted Shares Outstanding	0.00	-	127.25M	132.11M	148.91M	151.82M	150.94M	176.14M	308.98M
Weighted Average Basic & Diluted Shares Outstanding	0.00	-	127.25M	132.11M	299.82M	301.54M	303.62M	307.01M	309.97M

This table shows Amneal Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-2.69	-4.33	-6.94	12	9.68	-99	-92	5.99	-0.16	-31
Consolidated Net Income / (Loss)	-2.39	-5.86	-10	30	25	-93	-82	17	12	-21
Net Income / (Loss) Continuing Operations	-2.39	-5.86	-10	30	25	-93	-82	17	12	-21
Total Pre-Tax Income	2.18	-7.66	-9.43	30	23	-83	-76	20	15	-15
Total Operating Income	44	36	34	80	76	14	-11	95	89	76
Total Gross Profit	194	215	178	220	233	190	238	250	270	263
Total Revenue	546	610	558	599	620	617	659	702	702	731
Operating Revenue	546	610	558	599	620	617	659	702	702	731
Total Cost of Revenue	351	394	379	379	388	427	421	452	433	468
Operating Cost of Revenue	351	394	379	379	388	427	421	452	433	468
Total Operating Expenses	150	179	144	140	157	176	249	154	181	187
Selling, General & Admin Expense	100	102	102	106	113	109	113	116	119	129
Research & Development Expense	50	46	39	38	41	50	39	36	61	60
Other Operating Expenses / (Income)	0.09	-6.37	0.42	0.83	0.96	-3.35	0.98	1.04	1.97	-3.99
Restructuring Charge	0.62	0.10	0.51	0.08	1.04	0.11	1.47	0.22	0.17	0.49
Other Special Charges / (Income)	-1.14	24	2.02	-4.35	0.50	-11	94	0.70	-1.18	1.78
Total Other Income / (Expense), net	-42	-44	-44	-50	-53	-98	-65	-75	-73	-91
Interest & Investment Income	-42	-47	-49	-51	-51	-60	-66	-66	-66	-62
Other Income / (Expense), net	0.22	3.63	5.44	0.43	-1.78	2.70	0.93	-9.35	-7.88	-29
Income Tax Expense	4.57	-1.80	0.67	0.00	-2.08	9.86	6.16	3.62	3.67	5.42
Net Income / (Loss) Attributable to Noncontrolling Interest	0.30	-1.53	-3.15	18	15	5.31	9.97	11	12	10
Basic Earnings per Share	($0.02)	($0.03)	($0.05)	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)
Weighted Average Basic Shares Outstanding	151.39M	150.94M	152.11M	153.74M	154.22M	176.14M	307.28M	309.12M	309.65M	308.98M
Diluted Earnings per Share	($0.02)	($0.03)	($0.05)	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)
Weighted Average Diluted Shares Outstanding	151.39M	150.94M	152.11M	154.89M	159.69M	176.14M	307.28M	318.96M	309.65M	308.98M
Weighted Average Basic & Diluted Shares Outstanding	303.59M	303.62M	305.45M	306.31M	306.54M	307.01M	308.65M	309.54M	309.84M	309.97M

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-29	41	141	-66	194	-90	-222	64	19
Net Cash From Operating Activities	115	234	250	1.71	379	242	65	346	295
Net Cash From Continuing Operating Activities	115	234	250	1.71	379	242	65	346	295
Net Income / (Loss) Continuing Operations	209	169	-201	-604	69	20	-255	-49	-74
Consolidated Net Income / (Loss)	209	169	-201	-604	69	20	-255	-49	-74
Depreciation Expense	33	46	137	207	235	233	240	229	236
Amortization Expense	3.00	4.59	16	43	8.68	9.20	8.60	12	29
Non-Cash Adjustments To Reconcile Net Income	26	23	294	109	129	115	133	225	163
Changes in Operating Assets and Liabilities, net	-156	-8.51	3.78	246	-63	-136	-62	-72	-59
Net Cash From Investing Activities	-125	-99	-396	-20	-318	-194	-174	-69	-63
Net Cash From Continuing Investing Activities	-125	-99	-396	-20	-318	-194	-174	-69	-63
Purchase of Property, Plant & Equipment	-123	-95	-83	-47	-62	-51	-49	-47	-60
Acquisitions	-1.85	-20	-339	-50	-256	-148	-127	-22	-15
Divestitures	0.00	16	0.00	35	-	-	0.00	0.00	12
Other Investing Activities, net	-	0.00	0.00	43	0.00	5.00	1.00	0.00	0.00
Net Cash From Financing Activities	-19	-95	288	-46	132	-138	-107	-213	-212
Net Cash From Continuing Financing Activities	-19	-95	288	-46	132	-138	-107	-213	-212
Repayment of Debt	-43	-19	-839	-27	-40	-79	-125	-576	-233
Repurchase of Common Equity	-0.01	0.00	-12	-	0.00	0.00	-1.72	0.00	0.00
Payment of Dividends	-202	-376	-183	-	-3.24	-57	-18	-71	-20
Issuance of Debt	225	300	1,325	0.00	180	0.00	85	437	48
Other Financing Activities, net	-0.26	0.04	-3.76	-19	-4.92	-1.90	-47	-1.93	-6.80
Effect of Exchange Rate Changes	-	-	-0.67	-2.25	1.04	0.10	-5.68	0.07	-1.00
Cash Interest Paid	51	65	132	159	130	122	143	193	264
Cash Income Taxes Paid	4.92	-5.78	35	10	100	-16	13	2.50	15

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-2.29	-61	116	-36	-19	3.50	-47	-2.00	29	40
Net Cash From Operating Activities	94	-23	140	-11	81	136	-4.41	40	142	118
Net Cash From Continuing Operating Activities	94	-23	140	-11	81	136	-4.41	40	142	118
Net Income / (Loss) Continuing Operations	-2.39	-5.86	-10	30	25	-93	-82	17	12	-21
Consolidated Net Income / (Loss)	-2.39	-5.86	-10	30	25	-93	-82	17	12	-21
Depreciation Expense	62	61	58	57	57	57	56	56	59	66
Amortization Expense	2.10	2.11	2.06	2.47	2.36	4.66	0.29	0.93	1.44	26
Non-Cash Adjustments To Reconcile Net Income	23	52	35	27	30	133	39	27	39	59
Changes in Operating Assets and Liabilities, net	9.27	-133	55	-128	-33	34	-17	-61	31	-12
Net Cash From Investing Activities	-49	-11	-12	-12	-13	-32	-20	-6.47	-21	-16
Net Cash From Continuing Investing Activities	-49	-11	-12	-12	-13	-32	-20	-6.47	-21	-16
Purchase of Property, Plant & Equipment	-18	-11	-11	-11	-12	-12	-10	-11	-17	-22
Acquisitions	-32	-	-0.34	-1.15	-1.00	-20	-9.70	-0.75	-3.60	-0.60
Divestitures	-	-	-	-	-	-	-	-	-	7.01
Net Cash From Financing Activities	-46	-22	-13	-12	-87	-101	-23	-35	-92	-61
Net Cash From Continuing Financing Activities	-46	-22	-13	-12	-87	-101	-23	-35	-92	-61
Repayment of Debt	-43	-18	-73	-15	-64	-424	-63	-27	-87	-56
Payment of Dividends	-3.21	-4.43	-18	-17	-32	-3.01	-0.59	-8.29	-5.56	-5.36
Other Financing Activities, net	-0.27	-0.09	-2.02	-0.01	0.22	-0.11	-7.18	0.20	0.42	-0.24
Effect of Exchange Rate Changes	-0.40	-3.74	0.77	-0.60	-0.30	0.20	-0.17	-0.10	0.01	-0.74
Cash Interest Paid	35	51	41	48	48	56	65	72	66	61
Cash Income Taxes Paid	-3.20	23	3.42	0.50	-3.49	2.07	-4.57	15	-1.15	6.16

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	1,342	4,353	3,666	4,006	3,940	3,799	3,473	3,501
Total Current Assets	772	1,287	1,210	1,552	1,520	1,412	1,378	1,588
Cash & Equivalents	74	213	151	341	248	26	92	111
Restricted Cash	3.76	5.39	1.63	5.74	8.95	9.25	7.57	7.87
Accounts Receivable	368	482	606	640	664	742	615	776
Inventories, net	284	457	381	491	489	531	581	612
Prepaid Expenses	42	128	70	73	110	104	83	81
Plant, Property, & Equipment, net	487	544	478	478	514	470	448	425
Total Noncurrent Assets	83	2,522	2,109	1,977	1,905	1,918	1,647	1,489
Noncurrent Note & Lease Receivables	-	0.00	123	68	64	63	59	56
Goodwill	26	426	420	523	593	599	599	597
Intangible Assets	45	1,655	1,383	1,305	1,167	1,096	890	732
Other Noncurrent Operating Assets	11	68	184	81	81	159	99	102
Total Liabilities & Shareholders' Equity	1,342	4,353	3,666	4,006	3,940	3,799	3,473	3,501
Total Liabilities	1,717	3,456	3,319	3,649	3,556	3,590	3,411	3,546
Total Current Liabilities	297	554	550	677	677	753	847	1,130
Short-Term Debt	89	22	21	45	31	90	213	324
Accounts Payable	207	532	513	619	573	541	542	758
Other Current Liabilities	-	0.00	18	16	76	122	91	48
Total Noncurrent Liabilities	1,421	2,903	2,769	2,972	2,879	2,838	2,565	2,416
Long-Term Debt	1,355	2,631	2,609	2,772	2,718	2,592	2,427	2,162
Capital Lease Obligations	40	39	61	-	60	61	59	57
Asset Retirement Reserve & Litigation Obligation	-	-	-	-	-	-	0.32	85
Other Noncurrent Operating Liabilities	7.79	39	98	201	100	185	78	112
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	0.00	12	17	25	41	65
Total Equity & Noncontrolling Interests	-376	896	347	345	367	184	20	-110
Total Preferred & Common Equity	-386	505	232	303	360	298	20	-109
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-386	505	232	303	360	298	20	-109
Common Stock	11	533	610	631	661	695	542	563
Retained Earnings	-383	-21	-378	-287	-276	-406	-490	-607
Accumulated Other Comprehensive Income / (Loss)	-14	-7.76	-0.07	-41	-25	9.94	-32	-66
Noncontrolling Interest	10	392	115	42	6.63	-114	0.23	-0.25

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	3,874	3,627	3,701	3,687	3,456	3,510	3,461
Total Current Assets	1,420	1,307	1,422	1,456	1,380	1,485	1,513
Cash & Equivalents	87	145	109	87	47	44	74
Accounts Receivable	630	546	675	693	670	779	757
Inventories, net	544	529	551	576	571	576	596
Prepaid Expenses	150	81	82	91	87	82	82
Plant, Property, & Equipment, net	470	463	459	452	440	425	431
Total Noncurrent Assets	1,984	1,857	1,820	1,779	1,637	1,599	1,517
Noncurrent Note & Lease Receivables	64	62	62	61	60	58	58
Goodwill	600	599	599	599	599	599	598
Intangible Assets	1,159	1,055	1,015	983	859	820	780
Other Noncurrent Operating Assets	161	140	144	137	119	122	81
Total Liabilities & Shareholders' Equity	3,874	3,627	3,701	3,687	3,456	3,510	3,461
Total Liabilities	3,657	3,464	3,518	3,496	3,473	3,514	3,495
Total Current Liabilities	818	704	777	761	834	1,114	1,095
Short-Term Debt	90	130	150	107	213	436	365
Accounts Payable	535	482	534	561	576	632	684
Other Current Liabilities	193	92	90	90	43	44	47
Total Noncurrent Liabilities	2,839	2,761	2,741	2,735	2,639	2,400	2,399
Long-Term Debt	2,646	2,602	2,549	2,542	2,378	2,178	2,170
Asset Retirement Reserve & Litigation Obligation	-	-	-	-	85	85	85
Other Noncurrent Operating Liabilities	132	99	191	193	175	137	144
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	22	28	32	37	47	53	60
Total Equity & Noncontrolling Interests	194	135	151	154	-64	-57	-94
Total Preferred & Common Equity	297	294	318	331	-64	-57	-93
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	297	294	318	331	-64	-57	-93
Common Stock	687	704	711	719	542	549	556
Retained Earnings	-402	-413	-401	-392	-582	-576	-576
Accumulated Other Comprehensive Income / (Loss)	13	3.76	8.08	3.87	-24	-30	-74
Noncontrolling Interest	-103	-160	-167	-177	0.10	-0.02	-0.14

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	1.52%	60.88%	-2.20%	22.51%	5.08%	5.67%	8.20%	16.73%
EBITDA Growth	0.00%	-3.49%	-61.35%	73.44%	78.87%	15.81%	-61.17%	183.79%	3.71%
EBIT Growth	0.00%	-9.33%	-116.12%	-31.79%	311.81%	52.14%	-153.35%	336.05%	-3.59%
NOPAT Growth	0.00%	-12.78%	-105.68%	-1,164.08%	136.66%	53.91%	-167.66%	315.29%	22.00%
Net Income Growth	0.00%	-19.15%	-218.89%	-199.83%	111.36%	-70.59%	-1,363.21%	80.88%	-51.63%
EPS Growth	0.00%	0.00%	0.00%	-1,612.50%	122.26%	-88.52%	-1,328.57%	44.19%	20.83%
Operating Cash Flow Growth	0.00%	103.53%	6.85%	-99.32%	22,128.80%	-36.20%	-73.08%	430.84%	-14.61%
Free Cash Flow Firm Growth	0.00%	0.00%	-190.59%	107.72%	41.84%	-104.96%	-289.36%	905.93%	14.52%
Invested Capital Growth	0.00%	0.00%	222.00%	-10.52%	-6.37%	3.93%	-0.58%	-8.75%	-10.57%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-5.80%	6.00%	1.30%	3.41%	0.30%	4.24%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-20.15%	17.79%	-2.38%	15.75%	-5.11%	15.75%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-815.98%	75.29%	-6.38%	19.76%	-9.73%	16.91%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-22.95%	90.53%	-23.87%	20.75%	-41.99%	32.81%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	22.68%	544.71%	-40.09%	5.42%	-225.69%	49.57%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-5.79%	41.86%	-12.50%	1.15%	-900.00%	55.29%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	348.09%	-99.45%	70.60%	-15.01%	-57.07%	85.33%	-5.67%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	578.35%	-105.15%	68.89%	-4.74%	-0.08%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	4.89%	-4.67%	3.16%	-0.07%	-3.12%	-1.75%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	58.68%	50.90%	43.08%	21.70%	31.54%	36.73%	35.47%	34.28%	36.52%
EBITDA Margin	30.06%	28.58%	6.87%	12.18%	17.78%	19.60%	7.20%	18.89%	16.78%
Operating Margin	27.98%	23.71%	-1.18%	-15.29%	4.57%	7.29%	-4.29%	8.54%	8.92%
EBIT Margin	26.53%	23.69%	-2.37%	-3.20%	5.53%	8.01%	-4.04%	8.82%	7.29%
Profit (Net Income) Margin	20.57%	16.38%	-12.10%	-37.11%	3.44%	0.96%	-11.52%	-2.04%	-2.64%
Tax Burden Percent	97.49%	98.83%	99.30%	274.05%	-191.67%	64.31%	102.68%	120.99%	134.29%
Interest Burden Percent	79.53%	69.95%	513.43%	423.24%	-32.46%	18.70%	277.36%	-19.07%	-27.02%
Effective Tax Rate	2.51%	1.17%	0.00%	0.00%	0.00%	35.69%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	46.31%	-0.62%	-5.45%	2.19%	3.41%	-2.27%	5.13%	6.92%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	36.05%	-10.25%	-22.16%	2.37%	0.30%	-9.44%	-2.10%	-2.96%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-136.47%	-76.68%	-91.65%	17.31%	2.03%	-83.69%	-41.19%	-888.18%
Return on Equity (ROE)	0.00%	-90.17%	-77.31%	-97.10%	19.50%	5.45%	-85.96%	-36.06%	-881.26%
Cash Return on Invested Capital (CROIC)	0.00%	-153.69%	-105.84%	5.65%	8.76%	-0.44%	-1.69%	14.28%	18.09%
Operating Return on Assets (OROA)	0.00%	18.25%	-1.39%	-1.30%	2.87%	4.22%	-2.31%	5.81%	5.84%
Return on Assets (ROA)	0.00%	12.62%	-7.07%	-15.05%	1.79%	0.51%	-6.58%	-1.34%	-2.12%
Return on Common Equity (ROCE)	0.00%	-92.61%	-17.67%	-57.55%	14.83%	4.88%	-95.52%	-42.46%	4,703.59%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-43.90%	-39.88%	-260.15%	22.61%	5.60%	-85.38%	-246.31%	67.61%
Net Operating Profit after Tax (NOPAT)	278	242	-14	-174	64	98	-66	143	175
NOPAT Margin	27.28%	23.44%	-0.83%	-10.70%	3.20%	4.69%	-3.00%	5.98%	6.25%
Net Nonoperating Expense Percent (NNEP)	0.00%	10.26%	9.63%	16.71%	-0.19%	3.11%	7.17%	7.23%	9.89%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-2.27%	5.26%	7.17%
Cost of Revenue to Revenue	41.32%	49.10%	56.92%	78.30%	68.46%	63.27%	64.53%	65.72%	63.48%
SG&A Expenses to Revenue	11.66%	10.55%	13.70%	17.81%	16.40%	17.46%	18.07%	17.95%	17.05%
R&D to Revenue	17.58%	16.58%	11.68%	11.56%	9.03%	9.64%	9.04%	7.01%	7.04%
Operating Expenses to Revenue	30.70%	27.19%	44.26%	37.00%	26.96%	29.43%	39.76%	25.74%	27.60%
Earnings before Interest and Taxes (EBIT)	270	245	-39	-52	110	168	-89	211	204
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	306	295	114	198	354	410	159	452	469
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	8.00	6.21	4.52	4.01	2.02	94.07	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	2.43	0.89	0.69	0.69	0.27	0.78	0.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	15.04	135.93	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	6.65%	0.74%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	2.05	1.36	1.38	1.37	1.10	1.69	2.08
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	4.15	2.52	1.95	1.92	1.46	1.88	1.77
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	60.45	20.68	10.99	9.80	20.23	9.96	10.54
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	35.32	23.97	0.00	21.32	24.28
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	61.01	40.93	0.00	31.47	28.32
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	27.59	2,402.12	10.27	16.62	49.50	13.03	16.75
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	22.71	15.22	0.00	0.00	11.31	10.84
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	-3.95	3.00	7.76	7.90	7.32	13.13	44.03	-57.09
Long-Term Debt to Equity	0.00	-3.71	2.98	7.70	7.77	7.24	12.70	40.55	-49.82
Financial Leverage	0.00	-3.79	7.48	4.14	7.30	6.77	8.87	19.64	299.68
Leverage Ratio	0.00	-3.57	10.93	6.45	10.91	10.73	13.05	26.91	415.96
Compound Leverage Factor	0.00	-2.50	56.14	27.30	-3.54	2.01	36.21	-5.13	-112.40
Debt to Total Capital	0.00%	133.86%	75.02%	88.59%	88.76%	87.98%	92.92%	97.78%	101.78%
Short-Term Debt to Total Capital	0.00%	8.07%	0.61%	0.71%	1.43%	0.96%	3.05%	7.72%	12.98%
Long-Term Debt to Total Capital	0.00%	125.79%	74.41%	87.88%	87.33%	87.02%	89.87%	90.06%	88.81%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.92%	10.92%	3.78%	1.68%	0.74%	-3.03%	1.50%	2.59%
Common Equity to Total Capital	0.00%	-34.78%	14.07%	7.64%	9.56%	11.29%	10.11%	0.72%	-4.37%
Debt to EBITDA	0.00	5.03	23.57	13.59	7.95	6.85	17.22	5.97	5.42
Net Debt to EBITDA	0.00	4.76	21.65	12.82	6.97	6.22	17.00	5.75	5.17
Long-Term Debt to EBITDA	0.00	4.72	23.38	13.48	7.82	6.77	16.65	5.50	4.73
Debt to NOPAT	0.00	6.13	-195.44	-15.46	44.15	28.60	-41.28	18.87	14.57
Net Debt to NOPAT	0.00	5.81	-179.55	-14.59	38.71	25.99	-40.74	18.17	13.89
Long-Term Debt to NOPAT	0.00	5.76	-193.86	-15.34	43.44	28.29	-39.92	17.38	12.71
Altman Z-Score	0.00	0.00	1.25	0.73	0.98	1.07	0.66	1.20	1.32
Noncontrolling Interest Sharing Ratio	0.00%	-2.70%	77.15%	40.73%	23.91%	10.40%	-11.13%	-17.75%	633.73%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	2.60	2.32	2.20	2.29	2.24	1.88	1.63	1.41
Quick Ratio	0.00	1.49	1.26	1.38	1.45	1.35	1.02	0.83	0.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-804	-2,336	180	256	-13	-49	398	456
Operating Cash Flow to CapEx	93.73%	247.11%	433.34%	3.61%	612.91%	474.72%	133.42%	738.40%	489.06%
Free Cash Flow to Firm to Interest Expense	0.00	-317.55	-118.80	0.00	0.00	0.00	-169.76	9.76	0.00
Operating Cash Flow to Interest Expense	0.00	92.49	12.72	0.00	0.00	0.00	223.71	8.47	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	55.06	9.79	0.00	0.00	0.00	56.03	7.32	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.77	0.58	0.41	0.52	0.53	0.57	0.66	0.80
Accounts Receivable Turnover	0.00	2.81	3.91	2.99	3.20	3.21	3.15	3.53	4.02
Inventory Turnover	0.00	1.79	2.55	3.04	3.13	2.70	2.80	2.83	2.97
Fixed Asset Turnover	0.00	2.12	3.23	3.18	4.17	4.22	4.50	5.22	6.40
Accounts Payable Turnover	0.00	2.45	2.56	2.44	2.41	2.22	2.56	2.91	2.73
Days Sales Outstanding (DSO)	0.00	129.80	93.27	122.14	114.17	113.67	115.99	103.46	90.85
Days Inventory Outstanding (DIO)	0.00	204.29	142.91	120.14	116.62	135.02	130.41	129.03	122.85
Days Payable Outstanding (DPO)	0.00	149.17	142.58	149.85	151.56	164.31	142.40	125.61	133.75
Cash Conversion Cycle (CCC)	0.00	184.92	93.60	92.43	79.23	84.38	104.00	106.88	79.96
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1,046	3,369	3,015	2,823	2,933	2,916	2,661	2,380
Invested Capital Turnover	0.00	1.98	0.75	0.51	0.68	0.73	0.76	0.86	1.11
Increase / (Decrease) in Invested Capital	0.00	1,046	2,323	-354	-192	111	-17	-255	-281
Enterprise Value (EV)	0.00	0.00	6,904	4,096	3,893	4,020	3,222	4,502	4,943
Market Capitalization	0.00	0.00	4,040	1,442	1,370	1,444	604	1,861	2,454
Book Value per Share	$0.00	$0.00	$1.69	$0.78	$1.01	$1.20	$0.98	$0.06	($0.35)
Tangible Book Value per Share	$0.00	$0.00	($5.28)	($5.25)	($5.08)	($4.64)	($4.60)	($4.79)	($4.64)
Total Capital	0.00	1,109	3,588	3,039	3,174	3,193	2,952	2,760	2,498
Total Debt	0.00	1,485	2,691	2,692	2,817	2,809	2,743	2,699	2,543
Total Long-Term Debt	0.00	1,395	2,670	2,671	2,772	2,778	2,653	2,486	2,219
Net Debt	0.00	1,407	2,473	2,539	2,470	2,552	2,707	2,600	2,424
Capital Expenditures (CapEx)	123	95	58	47	62	51	49	47	60
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	487	536	528	573	617	714	645	664
Debt-free Net Working Capital (DFNWC)	0.00	565	755	681	920	873	749	744	782
Net Working Capital (NWC)	0.00	475	733	660	875	843	659	531	458
Net Nonoperating Expense (NNE)	68	73	188	429	-4.77	78	188	192	248
Net Nonoperating Obligations (NNO)	0.00	1,422	2,473	2,668	2,466	2,550	2,707	2,600	2,424
Total Depreciation and Amortization (D&A)	36	51	154	250	244	243	249	241	265
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	47.08%	32.21%	32.49%	28.74%	29.46%	32.26%	26.96%	23.76%
Debt-free Net Working Capital to Revenue	0.00%	54.62%	45.37%	41.89%	46.17%	41.72%	33.86%	31.10%	28.00%
Net Working Capital to Revenue	0.00%	45.96%	44.06%	40.57%	43.90%	40.26%	29.79%	22.20%	16.39%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.62	$0.07	($0.86)	($0.48)	($0.38)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	298.69M	299.23M	147.44M	148.92M	150.94M	176.14M	308.98M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.61	$0.07	($0.86)	($0.48)	($0.38)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	298.69M	299.23M	148.91M	151.82M	150.94M	176.14M	308.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	127.25M	132.11M	299.82M	301.54M	303.62M	307.01M	309.97M
Normalized Net Operating Profit after Tax (NOPAT)	292	223	195	-97	78	125	134	157	243
Normalized NOPAT Margin	28.69%	21.53%	11.71%	-5.98%	3.90%	5.96%	6.04%	6.56%	8.70%
Pre Tax Income Margin	21.10%	16.57%	-12.19%	-13.54%	-1.80%	1.50%	-11.22%	-1.68%	-1.97%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	96.73	-2.01	0.00	0.00	0.00	-307.42	5.18	0.00
NOPAT to Interest Expense	0.00	95.67	-0.70	0.00	0.00	0.00	-228.35	3.51	0.00
EBIT Less CapEx to Interest Expense	0.00	59.30	-4.94	0.00	0.00	0.00	-475.10	4.03	0.00
NOPAT Less CapEx to Interest Expense	0.00	58.24	-3.64	0.00	0.00	0.00	-396.03	2.36	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	96.26%	222.13%	-90.73%	0.00%	4.72%	283.25%	-6.89%	-145.48%	-26.81%
Augmented Payout Ratio	96.26%	222.13%	-96.58%	0.00%	4.72%	283.25%	-7.57%	-145.48%	-26.81%

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.21%	13.57%	12.04%	7.10%	13.65%	1.18%	18.23%	17.15%	13.29%	18.40%
EBITDA Growth	14.05%	26.71%	19.99%	203.60%	23.23%	-23.67%	-54.05%	1.81%	5.92%	76.98%
EBIT Growth	37.75%	124.88%	70.36%	140.85%	65.73%	-57.41%	-124.62%	6.96%	9.57%	174.35%
NOPAT Growth	-343.61%	222.43%	47.82%	157.60%	269.64%	-60.61%	-131.19%	-1.93%	-17.93%	434.02%
Net Income Growth	60.77%	71.37%	-56.25%	112.36%	1,147.41%	-1,493.44%	-709.17%	-43.45%	-53.03%	77.78%
EPS Growth	33.33%	25.00%	-400.00%	110.00%	400.00%	-1,800.00%	-500.00%	-75.00%	-100.00%	82.46%
Operating Cash Flow Growth	13.61%	-136.82%	16.09%	90.96%	-13.02%	683.13%	-103.16%	449.55%	74.20%	-13.06%
Free Cash Flow Firm Growth	-189.99%	141.01%	183.97%	249.85%	305.42%	526.92%	17.47%	20.41%	54.67%	26.21%
Invested Capital Growth	2.64%	-0.58%	-6.85%	-5.40%	-5.87%	-8.75%	-9.91%	-7.51%	-11.83%	-10.57%
Revenue Q/Q Growth	-2.47%	11.77%	-8.56%	7.44%	3.50%	-0.49%	6.84%	6.46%	0.10%	3.99%
EBITDA Q/Q Growth	180.08%	-5.04%	-2.65%	39.96%	-4.75%	-41.18%	-38.77%	210.08%	-0.91%	-1.72%
EBIT Q/Q Growth	122.61%	-11.01%	0.57%	101.85%	-8.26%	-77.13%	-158.13%	977.12%	-6.03%	-42.74%
NOPAT Q/Q Growth	65.03%	151.87%	-4.39%	232.10%	3.00%	-87.96%	-175.71%	1,144.14%	-13.81%	-21.63%
Net Income Q/Q Growth	99.00%	-145.10%	-72.31%	394.07%	-15.67%	-472.88%	12.50%	120.55%	-29.96%	-276.42%
EPS Q/Q Growth	97.50%	-50.00%	-66.67%	260.00%	-25.00%	-1,050.00%	47.37%	106.67%	-100.00%	0.00%
Operating Cash Flow Q/Q Growth	174.55%	-124.89%	699.83%	-108.12%	817.38%	66.89%	-103.25%	999.25%	257.50%	-16.71%
Free Cash Flow Firm Q/Q Growth	22.25%	134.21%	444.40%	3.49%	6.59%	4.40%	-25.36%	6.07%	36.92%	-14.81%
Invested Capital Q/Q Growth	-0.36%	-0.07%	-3.88%	-1.15%	-0.86%	-3.12%	-1.51%	1.48%	-5.48%	-1.75%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	35.60%	35.32%	31.96%	36.73%	37.50%	30.77%	36.11%	35.62%	38.37%	35.98%
EBITDA Margin	19.85%	16.86%	17.95%	23.39%	21.52%	12.72%	6.98%	20.32%	20.12%	19.02%
Operating Margin	8.13%	5.91%	6.18%	13.37%	12.20%	2.30%	-1.63%	13.60%	12.64%	10.38%
EBIT Margin	8.17%	6.50%	7.15%	13.44%	11.91%	2.74%	-1.49%	12.27%	11.52%	6.34%
Profit (Net Income) Margin	-0.44%	-0.96%	-1.81%	4.96%	4.04%	-15.13%	-12.39%	2.39%	1.67%	-2.84%
Tax Burden Percent	-109.63%	76.53%	107.09%	100.08%	109.04%	111.84%	108.15%	82.27%	76.23%	135.40%
Interest Burden Percent	4.89%	-19.30%	-23.63%	36.84%	31.08%	-494.09%	769.14%	23.69%	19.06%	-33.06%
Effective Tax Rate	209.63%	0.00%	0.00%	0.00%	-9.04%	0.00%	0.00%	17.73%	23.77%	0.00%
Return on Invested Capital (ROIC)	-6.62%	3.13%	3.38%	10.84%	11.21%	1.38%	-1.07%	10.90%	9.99%	8.05%
ROIC Less NNEP Spread (ROIC-NNEP)	-4.82%	1.95%	2.07%	8.95%	9.02%	-2.51%	-3.93%	8.51%	7.76%	5.11%
Return on Net Nonoperating Assets (RNNOA)	-40.35%	17.26%	18.48%	127.57%	116.24%	-49.29%	-139.92%	245.25%	246.67%	1,532.19%
Return on Equity (ROE)	-46.97%	20.39%	21.87%	138.42%	127.45%	-47.91%	-140.99%	256.15%	256.66%	1,540.24%
Cash Return on Invested Capital (CROIC)	-5.51%	-1.69%	5.07%	10.79%	14.75%	14.28%	14.61%	12.39%	17.65%	18.09%
Operating Return on Assets (OROA)	4.45%	3.72%	4.33%	8.03%	7.52%	1.80%	-1.05%	8.84%	8.64%	5.08%
Return on Assets (ROA)	-0.24%	-0.55%	-1.09%	2.96%	2.55%	-9.96%	-8.73%	1.72%	1.26%	-2.28%
Return on Common Equity (ROCE)	-49.48%	22.66%	25.58%	221.65%	196.25%	-56.42%	-223.40%	373.47%	386.42%	-8,220.83%
Return on Equity Simple (ROE_SIMPLE)	-90.56%	0.00%	-87.78%	3.56%	11.72%	0.00%	188.79%	231.80%	156.78%	0.00%
Net Operating Profit after Tax (NOPAT)	-49	25	24	80	82	9.94	-7.52	79	68	53
NOPAT Margin	-8.91%	4.14%	4.33%	13.37%	13.30%	1.61%	-1.14%	11.19%	9.64%	7.26%
Net Nonoperating Expense Percent (NNEP)	-1.80%	1.18%	1.31%	1.89%	2.19%	3.89%	2.86%	2.40%	2.23%	2.94%
Return On Investment Capital (ROIC_SIMPLE)	-	0.86%	-	-	-	0.37%	-	-	-	2.18%
Cost of Revenue to Revenue	64.40%	64.68%	68.04%	63.27%	62.50%	69.23%	63.89%	64.38%	61.63%	64.02%
SG&A Expenses to Revenue	18.34%	16.75%	18.31%	17.62%	18.23%	17.67%	17.08%	16.60%	16.90%	17.62%
R&D to Revenue	9.21%	7.59%	6.94%	6.31%	6.67%	8.09%	5.96%	5.14%	8.70%	8.23%
Operating Expenses to Revenue	27.47%	29.41%	25.78%	23.36%	25.30%	28.47%	37.74%	22.01%	25.73%	25.61%
Earnings before Interest and Taxes (EBIT)	45	40	40	81	74	17	-9.82	86	81	46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	108	103	100	140	133	78	46	143	141	139
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.06	2.02	1.43	2.98	3.91	94.07	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.29	0.27	0.19	0.41	0.54	0.78	0.75	0.75	0.96	0.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	125.22	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.80%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.11	1.10	1.05	1.23	1.35	1.69	1.76	1.79	2.10	2.08
Enterprise Value to Revenue (EV/Rev)	1.51	1.46	1.29	1.47	1.56	1.88	1.78	1.76	1.90	1.77
Enterprise Value to EBITDA (EV/EBITDA)	23.50	20.23	16.65	7.54	7.80	9.96	11.28	11.54	12.58	10.54
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	16.62	15.88	21.32	27.57	27.43	29.26	24.28
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	22.76	15.06	31.47	39.95	37.50	38.78	28.32
Enterprise Value to Operating Cash Flow (EV/OCF)	21.33	49.50	34.70	17.13	19.92	13.03	22.10	18.15	16.29	16.75
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	19.89	11.06	8.89	11.31	11.44	13.87	11.17	10.84
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	12.91	13.13	17.21	14.76	13.84	44.03	-155.98	-642.51	-75.25	-57.09
Long-Term Debt to Equity	12.50	12.70	16.41	13.94	13.28	40.55	-143.18	-535.43	-64.42	-49.82
Financial Leverage	8.37	8.87	8.92	14.25	12.89	19.64	35.60	28.83	31.78	299.68
Leverage Ratio	12.76	13.05	12.82	20.72	18.53	26.91	48.65	40.33	45.33	415.96
Compound Leverage Factor	0.62	-2.52	-3.03	7.63	5.76	-132.96	374.20	9.55	8.64	-137.50
Debt to Total Capital	92.81%	92.92%	94.51%	93.66%	93.26%	97.78%	100.65%	100.16%	101.35%	101.78%
Short-Term Debt to Total Capital	2.98%	3.05%	4.40%	5.22%	3.75%	7.72%	8.26%	16.69%	14.58%	12.98%
Long-Term Debt to Total Capital	89.83%	89.87%	90.11%	88.44%	89.51%	90.06%	92.38%	83.46%	86.76%	88.81%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-2.68%	-3.03%	-4.48%	-4.69%	-4.91%	1.50%	1.83%	2.05%	2.39%	2.59%
Common Equity to Total Capital	9.87%	10.11%	9.97%	11.04%	11.65%	0.72%	-2.48%	-2.20%	-3.74%	-4.37%
Debt to EBITDA	20.33	17.22	15.87	5.98	5.56	5.97	6.56	6.58	6.26	5.42
Net Debt to EBITDA	19.63	17.00	15.01	5.74	5.38	5.75	6.45	6.47	6.07	5.17
Long-Term Debt to EBITDA	19.67	16.65	15.13	5.65	5.33	5.50	6.02	5.48	5.36	4.73
Debt to NOPAT	-33.37	-41.28	-47.61	18.06	10.74	18.87	23.25	21.38	19.29	14.57
Net Debt to NOPAT	-32.22	-40.74	-45.03	17.33	10.39	18.17	22.83	21.03	18.72	13.89
Long-Term Debt to NOPAT	-32.29	-39.92	-45.39	17.05	10.31	17.38	21.34	17.82	16.51	12.71
Altman Z-Score	0.73	0.78	0.78	0.92	1.01	1.02	0.99	1.05	1.21	1.17
Noncontrolling Interest Sharing Ratio	-5.35%	-11.13%	-16.98%	-60.13%	-53.99%	-17.75%	-58.45%	-45.80%	-50.56%	633.73%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.74	1.88	1.86	1.83	1.91	1.63	1.65	1.33	1.38	1.41
Quick Ratio	0.88	1.02	0.98	1.01	1.02	0.83	0.86	0.74	0.76	0.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-124	42	230	238	254	265	270	287	393	334
Operating Cash Flow to CapEx	533.71%	-203.14%	1,225.65%	-101.90%	652.35%	1,151.82%	-43.84%	370.49%	828.51%	525.63%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.55	0.57	0.60	0.60	0.63	0.66	0.70	0.72	0.75	0.80
Accounts Receivable Turnover	3.40	3.15	4.19	3.39	3.61	3.53	4.10	3.57	3.70	4.02
Inventory Turnover	2.64	2.80	2.85	2.78	2.75	2.83	2.94	3.00	2.96	2.97
Fixed Asset Turnover	4.60	4.50	4.72	4.90	5.18	5.22	5.53	5.87	6.07	6.40
Accounts Payable Turnover	2.43	2.56	2.86	2.68	2.81	2.91	3.05	2.90	2.78	2.73
Days Sales Outstanding (DSO)	107.46	115.99	87.17	107.76	101.18	103.46	88.96	102.11	98.67	90.85
Days Inventory Outstanding (DIO)	138.35	130.41	128.07	131.48	132.74	129.03	124.28	121.79	123.51	122.85
Days Payable Outstanding (DPO)	150.45	142.40	127.64	135.95	129.93	125.61	119.54	126.07	131.14	133.75
Cash Conversion Cycle (CCC)	95.35	104.00	87.59	103.28	103.99	106.88	93.70	97.82	91.04	79.96
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,919	2,916	2,803	2,771	2,747	2,661	2,525	2,563	2,422	2,380
Invested Capital Turnover	0.74	0.76	0.78	0.81	0.84	0.86	0.94	0.97	1.04	1.11
Increase / (Decrease) in Invested Capital	75	-17	-206	-158	-171	-255	-278	-208	-325	-281
Enterprise Value (EV)	3,234	3,222	2,931	3,402	3,715	4,502	4,451	4,583	5,095	4,943
Market Capitalization	613	604	422	947	1,293	1,861	1,860	1,960	2,575	2,454
Book Value per Share	$0.98	$0.98	$0.97	$1.04	$1.08	$0.06	($0.21)	($0.19)	($0.30)	($0.35)
Tangible Book Value per Share	($4.81)	($4.60)	($4.48)	($4.24)	($4.08)	($4.79)	($4.96)	($4.78)	($4.76)	($4.64)
Total Capital	3,014	2,952	2,954	2,882	2,840	2,760	2,574	2,609	2,501	2,498
Total Debt	2,798	2,743	2,792	2,700	2,648	2,699	2,590	2,613	2,534	2,543
Total Long-Term Debt	2,708	2,653	2,662	2,549	2,542	2,486	2,378	2,178	2,170	2,219
Net Debt	2,702	2,707	2,641	2,590	2,561	2,600	2,544	2,569	2,460	2,424
Capital Expenditures (CapEx)	18	11	11	11	12	12	10	11	17	22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	596	714	583	686	715	645	712	763	709	664
Debt-free Net Working Capital (DFNWC)	692	749	734	795	802	744	758	807	783	782
Net Working Capital (NWC)	602	659	604	644	695	531	546	371	418	458
Net Nonoperating Expense (NNE)	-46	31	34	50	57	103	74	62	56	74
Net Nonoperating Obligations (NNO)	2,702	2,707	2,641	2,588	2,556	2,600	2,542	2,567	2,456	2,424
Total Depreciation and Amortization (D&A)	64	63	60	60	60	62	56	57	60	93
Debt-free, Cash-free Net Working Capital to Revenue	27.85%	32.26%	25.64%	29.65%	29.96%	26.96%	28.53%	29.36%	26.44%	23.76%
Debt-free Net Working Capital to Revenue	32.33%	33.86%	32.28%	34.38%	33.61%	31.10%	30.39%	31.05%	29.20%	28.00%
Net Working Capital to Revenue	28.13%	29.79%	26.57%	27.87%	29.14%	22.20%	21.87%	14.29%	15.60%	16.39%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	($0.03)	($0.05)	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	151.39M	150.94M	152.11M	153.74M	154.22M	176.14M	307.28M	309.12M	309.65M	308.98M
Adjusted Diluted Earnings per Share	($0.02)	($0.03)	($0.05)	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	151.39M	150.94M	152.11M	154.89M	159.69M	176.14M	307.28M	318.96M	309.65M	308.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	303.59M	303.62M	305.45M	306.31M	306.54M	307.01M	308.65M	309.54M	309.84M	309.97M
Normalized Net Operating Profit after Tax (NOPAT)	31	42	26	53	54	2.42	60	79	67	55
Normalized NOPAT Margin	5.62%	6.93%	4.64%	8.86%	8.71%	0.39%	9.05%	11.30%	9.53%	7.48%
Pre Tax Income Margin	0.40%	-1.26%	-1.69%	4.95%	3.70%	-13.53%	-11.46%	2.91%	2.20%	-2.10%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-12.47%	-6.89%	-12.62%	380.88%	186.51%	-145.48%	-44.27%	-33.19%	-11.91%	-26.81%
Augmented Payout Ratio	-13.11%	-7.57%	-12.62%	380.88%	186.51%	-145.48%	-44.27%	-33.19%	-11.91%	-26.81%

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

When does Amneal Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Amneal Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amneal Pharmaceuticals' net income changed over the last 8 years?

Amneal Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$73.88 million in 2024, falling from $209.43 million in 2016. The previous period was -$48.72 million in 2023.

What is Amneal Pharmaceuticals's operating income?

Amneal Pharmaceuticals's total operating income in 2024 was $249.33 million, based on the following breakdown:

Total Gross Profit: $1.02 billion
Total Operating Expenses: $771.11 million

How has Amneal Pharmaceuticals revenue changed over the last 8 years?

Over the last 8 years, Amneal Pharmaceuticals' total revenue changed from $1.02 billion in 2016 to $2.79 billion in 2024, a change of 174.4%.

How much debt does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals' total liabilities were at $3.55 billion at the end of 2024, a 3.9% increase from 2023, and a 106.5% increase since 2017.

How much cash does Amneal Pharmaceuticals have?

In the past 7 years, Amneal Pharmaceuticals' cash and equivalents has ranged from $25.98 million in 2022 to $341.38 million in 2020, and is currently $110.55 million as of their latest financial filing in 2024.

How has Amneal Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Amneal Pharmaceuticals' book value per share changed from 0.00 in 2016 to -0.35 in 2024, a change of -35.3%.

Remove Ads

Related Companies

This page (NASDAQ:AMRX) was last updated on 4/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Financials

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Financials

Annual Income Statements for Amneal Pharmaceuticals

Quarterly Income Statements for Amneal Pharmaceuticals

Annual Cash Flow Statements for Amneal Pharmaceuticals

Quarterly Cash Flow Statements for Amneal Pharmaceuticals

Annual Balance Sheets for Amneal Pharmaceuticals

Quarterly Balance Sheets for Amneal Pharmaceuticals

Annual Metrics and Ratios for Amneal Pharmaceuticals

Quarterly Metrics and Ratios for Amneal Pharmaceuticals

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools